< CE News
Chronic Lymphocytic Leukemia: Evolving Treatment Strategies and the Role of the Specialty Pharmacist in Improving Patient Outcomes
Thu, Apr 04, 2019 6:51 PM UTC
Date: Thursday, May 2, 2019
Location: Wynn and Encore Hotels
3131 S Las Vegas Boulevard
Las Vegas, Nevada 89109
Time: 12:00 pm – 1:30 pm
*Lunch will be available
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, with over 20,000 patients diagnosed annually in the United States. The body of literature has grown tremendously in the past 6 to 12 months, with evidence demonstrating that oral oncolytics have a substantial and evolving role in the treatment paradigm for CLL. Specialty pharmacists are uniquely positioned to manage and counsel patients as well as advise health care professionals about adverse events and novel guideline-recommended targeted options. This presentation will provide information on the current and emerging therapies for patients with CLL, how to incorporate these agents into specific treatment regimens, and the pharmacist’s role in developing patient-centered solutions including adherence strategies, patient self-care management, implications of financial toxicity, and coordination of care.
- Identify disease- and patient-specific prognostic factors that guide selection of therapeutic options for patients with CLL
- Analyze current treatment strategies for CLL based on evidence for efficacy and safety
- Recognize appropriate prevention and management of therapy-induced adverse effects
- Explain the role of the pharmacist in improving adherence and disease outcomes in patients receiving CLL therapy
Victoria T. Brown, PharmD, BCOP
Clinical Pharmacy Lead, HPS Specialty Strategies
Kirollos S. Hanna, PharmD, BCPS, BCOP
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Hematology/Oncology Clinical Pharmacist
Univ. of Minnesota Medical Center & Mayo Clinic
This activity is supported by an educational grant from AstraZeneca.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-19-077-L01-P. The activity is available for CE credit for May 2, 2019.
All participants who attended the live symposium need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Detailed instructions on obtaining credit will be provided at the session. Credit must be requested no later than July 2, 2019.